Bedrocan Announces Management Change

TORONTO, May 5, 2015 /CNW/ - Bedrocan Cannabis Corp. (TSXV: BED) ("Bedrocan" or the "Company") announced that CFO Michael Singer will be leaving the Company at the end of June to pursue his career in his native Montreal. Mr. Singer will continue working with Bedrocan through this period on a part-time basis to ensure a smooth transition.

The company has also announced that Amy Stephenson will be joining the company this month and will assume the CFO duties when Mr. Singer leaves.  Ms. Stephenson is a seasoned financial executive and has over 10 years of experience as a CFO of public companies.

"Michael has been instrumental in building a solid financial foundation on which to grow our business, including taking Bedrocan public," said Marc Wayne, President and CEO. "It has been a pleasure to have Michael on our team and we are pleased that Amy has joined us to help Bedrocan complete our transition to operational profitability, anticipated later this year. "

About Bedrocan

Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan's strains represent the world's only standardized (pharmaceutical grade), full-bud medicinal cannabis, and have been used by more than 20,000 patients in seven countries, including Canada. The Company is committed to clinical research, and has a commitment to quality with ISO 9001-rated production processes and product development, on an international scale. Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol "BED". www.bedrocan.ca

Forward-Looking Statements

Certain information in this release are forward-looking statements with respect to the development plans and growth targets of the Company. Forward-looking statements consist of statements that are not purely historical, including statements regarding beliefs, plans, expectations or intensions for the future, and include, but not limited to, statements with respect to: (a) the commencement of domestic production of medicinal cannabis by the Company, and capacity for such production; (b) the Company's plan to scale up the volume of its product available to Canadian patients; and (c) the success of the Company's import and domestic production strategy.  The basis for the assumptions underlying such statements include that: (i) Bedrocan's existing licenses will remain in full force and effect, and be renewed upon terms acceptable to Bedrocan in the future; (ii) actual results of the Company's planned domestic production and development activities will continue to be positive and proceed as planned; (iii) all requisite regulatory and governmental approvals will be received on a timely basis on terms acceptable to the Company, and (iv) economic, political and industry market conditions will be favourable. However, such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including, but not limited to: (1) the risk that domestic production may not be achieved as planned; (2) changes in project parameters as plans evolve; (3) dependence on regulatory approvals and changes in legislation, environmental compliance, community support and the political and economic climate; (4) availability of future financing; and (5) the timely completion of the Company's production facility and other factors beyond the control of the Company. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.  The Company assumes no obligation to update such information, except as may be required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Bedrocan Cannabis Corp.

Cam Battley, Bedrocan Cannabis Corp., [email protected], +1.905.864.5525, www.bedrocan.ca; Investor relations: Jennifer Wood, TMX Equicom, [email protected], +1.416.815.0700, ext. 226